Allergan, Inc. received approval from the FDA for Lumigan (bimatoprost ophthalmic solution) 0.01% as a first-line therapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Lumigan 0.01% is an optimized reformulation of Lumigan 0.03%. The drug will be available in 4Q10. A three-month study of patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, showed Lumigan 0.01% lowered IOP as muc...